Company
Kenai Therapeutics
pioneering next generation approaches to cure neurological conditions.
Also known as KENAI Therapeutics Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- KENAI Therapeutics Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are a clinical-stage biotechnology company advancing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for the treatment of neurological conditions. Our aim is to deliver disease-modifying and potentially curative treatments that go beyond symptom management to reverse the impact of neurodegeneration – with the goal of restoring quality of life.
Funding snapshot
- Total raised
- $90MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Grant, $8M2026-01-05
Funding rounds
- Grant
- $8M2026-01-05, Company stated
- Series A
- $82M2024-02-29, Company stated
Products
- Other
- RNDP-001
Loading relationship preview